Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absolute, ACA, AllerganProlacriacommercialization, AMP, andDiquasthat, andPatadaycurrently, Andrew, aProlacriaproduct, Aton, AzaSiteof, benchmark, bifurcated, bottle, Brier, carrier, comparingAzaSiteto, counter, Creek, deadline, debarment, decree, Diquasophthalmic, double, driven, DSU, easier, expend, exploratory, Finorga, forRestasisin, France, futureProlacriadevelopment, gradual, hereinafter, hydrochloride, includingProlacria, installing, Johnson, jurisdictional, Koven, licensure, manufactureAzaSiteand, mentioned, modification, nationwide, NC, nonsubstantive, Novasep, Obama, ofAzaSiteduring, ofAzaSitethat, ofElestatwith, offerProlacriacommercialization, OIG, online, ourAzaSiteinventory, Parent, Partnership, passed, Patanol, PharmaForce, photographic, PHS, predicate, premium, procuring, Raleigh, raw, relieve, relocated, repackaging, Republic, researchingAzaSite, RSU, shortfall, smoothing, specialty, spoilage, step, stepped, straight, stream, subsidiary, teaching, tenant, tentative, theProlacriaclinical, thereof, therewith, tiered, toProlacriain, unapproved, unusable, user, VA, vacated, Valeant, warehousing, wrongful, Zymaxid
Removed:
absence, academic, accelerate, accelerated, accelerating, acceleration, adjacent, aged, airflow, ancillary, andTOBI, approveProlacria, Asia, aspect, aztreonam, Bank, bind, Blvd, Boehringer, break, breaking, broker, budgeted, capability, carcinogenicity, commercializeProlacriaworldwide, communication, comparing, concomitant, confirm, consignment, consistent, constant, contingency, convertible, credited, debit, decelerating, dedicated, Deduction, defer, dehydrated, delivered, demonstrated, depository, device, discounting, disposed, disrupting, DNA, dollar, Electric, embedded, emerge, emerging, Emperor, essentially, exchanged, expertise, feature, field, fluctuating, function, gene, Genentech, Gilead, goal, guaranteed, humor, hypertonic, IC, identifying, inElestat, Ingelheim, inhalation, inhaled, innovative, insolvent, insufficient, internationally, intervention, intraocular, jet, lending, lung, Lynch, measuring, mechanism, Merrill, meshwork, mg, minimal, nebulizer, newly, obstruction, ofElestatwill, ofProlacriaand, orProlacria, outflow, oversee, par, Park, partnering, portable, preceding, prefer, prepaid, prepayment, preserved, progressive, protein, Pulmozyme, ratio, reached, relationship, researching, resold, resolution, respiratory, retired, Royal, saline, satisfactory, seized, sellProlacria, sentence, Silicon, smaller, stocking, sustaining, systemic, thatProlacria, thickened, toElestat, trabecular, transportation, treated, Triangle, uncured, validated, Valley, vial, withProlacria, withZithromax
Filing tables
Filing exhibits
- 10-K Annual report
- 10.57 Amended and Restated Director Compensation Policy, Dated November 17, 2010
- 23.1 Consent of Pricewaterhousecoopers LLC
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14(A)/15D-14(A)
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14(A)/15D-14(A)
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Related press release
ISPH similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-169791 and 333-147733) and Form S-8 (Nos. 333-56360, 333-130496, 333-148185, 333-165555, 333-166955, 333-169366 and 333-169369) of Inspire Pharmaceuticals, Inc. of our report dated February 24, 2011 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
February 24, 2011